Ads
related to: iron ferrochel vs ferrous sulfate ec 325 mg tablet side effects
Search results
Results From The WOW.Com Content Network
Common side effects include constipation, abdominal pain, dark stools, and diarrhea. [14] Other side effects, which may occur with excessive use, include iron overload and iron toxicity. [11] [13] Ferrous salts used as supplements by mouth include ferrous fumarate, ferrous gluconate, ferrous succinate, and ferrous sulfate. [13]
220 mg (44 mg iron) per 5 mL* Ferrous Sulfate Elixir: 300 mg (60 mg iron) per 5 mL: Ferrous Sulfate Solution: 125 mg (25 mg iron) per mL* Fer-Gen-Sol® Drops: Teva Fer-In-Sol® Drops: Mead Johnson Tablets: 195 mg (39 mg iron)* Mol-Iron® Schering-Plough 300 mg (60 mg iron)* Feratab® Upsher-Smith 325 mg (65 mg iron)* Tablet, enteric-coated
The amount of elemental iron in an iron supplement can be calculate based on the percentage it constitutes for per tablet. For example, a 300 mg tablet of ferrous fumarate will contain 100 mg of elemental iron or 33%. Ferrous sulfate contains 20% elemental iron per mg of mineral salt; Ferrous gluconate contains 12% elemental iron per mg of ...
Iron(II) sulfate (British English: iron(II) sulphate) or ferrous sulfate denotes a range of salts with the formula Fe SO 4 ·xH 2 O. These compounds exist most commonly as the heptahydrate (x = 7) but several values for x are known. The hydrated form is used medically to treat or prevent iron deficiency, and also for industrial applications.
Iron(III)-hydroxide polymaltose complex is a medication used to treat iron deficiency / iron deficiency anemia and belongs to the group of oral iron preparations.The preparation is a macromolecular complex, consisting of iron(III) hydroxide (trivalent iron, Fe 3+, Fe(OH) 3 ·H 2 O) and the carrier polymaltose and is available in solid form as a film-coated or chewable tablet and in liquid form ...
Sodium ferric gluconate complex, sold under the brand name Ferrlecit, is an intravenously administered iron medication for the treatment of iron deficiency anemia in adults and in children aged six years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. [2]